TY - CHAP M1 - Book, Section TI - Clinical Outcomes with Self-Expanding Transcatheter Aortic Valve Bioprostheses A1 - Popma, Jeffrey J. A2 - Samady, Habib A2 - Fearon, William F. A2 - Yeung, Alan C. A2 - King III, Spencer B. Y1 - 2017 N1 - T2 - Interventional Cardiology, 2e AB - Since the introduction of the 18-Fr CoreValve self-expanding transcatheter aortic valve replacement (TAVR), over 70,000 implants have been performed worldwide. The use of this self-expanding bioprosthesis has provided an alternative to surgery in patients who are suboptimal for conventional surgical aortic valve replacement and has resulted in improved survival and quality of life for thousands of patients worldwide. There are a number of potential advantages of a self-expanding bioprosthesis over alternative transcatheter designs, including the progressive self-expansion of the inflow frame reducing the degree of paravalvular regurgitation (PVR) over time; supra-annular location of the porcine pericardial valve, which improves hemodynamics and potentially improves long-term durability; and large cell diameter, which provides access to coronary arteries after implantation. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesscardiology.mhmedical.com/content.aspx?aid=1146603756 ER -